Joseph Pidala is an Oncology physician affiliated with Moffitt Cancer Center. OpenAlex indexes 569 publications with 12,979 citations (h-index 59); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12902 Usf Magnolia Dr
Tampa, FL 336129416
Telephone
813-745-7365Provider last certified this registry record 20 Mar 2025.
Clinical trials
- CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SANOFI-AVENTIS U.S. LLCProgram year20253 payments
- National Marrow Donor ProgramProgram year20252 payments
- SANOFI-AVENTIS U.S. LLCProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
33.3%Selective immunosuppressants20.5%Rezurock100%Part D≥11 patientsKinase inhibitor7.7%Sirolimus59%Jakafi41%Part D<11 patients+ 1 more class in this area
Nervous system
26.4%Opioid Agonist12.3%Oxycodone Hcl70%Tramadol Hcl30%Part D<11 patientsgamma-Aminobutyric Acid A Receptor Positive Modulator4.1%Zolpidem Tartrate100%Part D<11 patients+ 3 more classes in this area
Dermatology
17.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor13.4%Acyclovir100%Part D≥21 patientsCorticosteroid3.9%Triamcinolone Acetonide100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2015–2026 per NIH RePORTER. The latest:
- Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical Centers - UG1
H. Lee Moffitt Cancer Ctr & Res Inst
FY2026$214,179UG1HL108987 - Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical Centers - UG1
H. Lee Moffitt Cancer Ctr & Res Inst
FY2025$214,179UG1HL108987 - Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical Centers - UG1
H. Lee Moffitt Cancer Ctr & Res Inst
FY2024$214,179UG1HL108987
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force
Biology of Blood and Marrow Transplantation
2022 - National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report
Biology of Blood and Marrow Transplantation
2021 - Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide
Biology of Blood and Marrow Transplantation
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Ignacio Wistuba, MD
Moffitt Cancer Center
Christine Chung, MD
Moffitt Cancer Center
Peter Forsyth, MD
Moffitt Cancer Center
Eric Haura, MD
Moffitt Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”